Uchida et al.3reported osimertinib‐induced interstitial lung disease (ILD) in three of 12 patients who received this third‐generation EGFR–TKI immediately after anti‐PD‐1 antibodies; however, EGFR–TKI‐induced ILD was not observed in five patients treated with first‐ or second‐generation EGFR–TKIs. Here, EGFR is linked to interstitial lung disease.